CervoMed Presents Initial Results of Phase 2a Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Showing Positive Effects on a Key Neurodegeneration Biomarker in Late-Breaking Oral Session at ISFTD 2026
CervoMed presented initial Phase 2a data showing neflamapimod reduced mean plasma NfL, a key neurodegeneration biomarker, over the first 12 weeks of open-label treatment in nfvPPA, a form of frontotemporal dementia with no approved treatments. In participants with baseline NfL at or above the median, the mean decline was approximately 5.7 pg/mL over 12 weeks; the drug was generally well tolerated with no new safety signals.
Key figures
- Drug Name
- neflamapimod
- Phase Of Trial
- Phase 2a
- Enrollment
- 25
- Trial duration weeks
- 36
- Mean baseline nfl pg ml
- 45.7
- Mean baseline gfap pg ml
- 103.4
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.